Darunavir

Dolutegravir

Viral load

Virology

Zidovudine

Viral disease

Tenofovir

Antiretroviral therapy

Human immunodeficiency virus (HIV)

Medicine

New England Journal of Medicine

The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine.

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV